Dr. Jody Voorspoels, Chairman
Jody is a pharmacist graduated from Ghent University and holds a Ph.D. in pharmaceutical technology from Ghent University. Jody's Ph.D. work focused on the use of bioadhesive drug delivery systems for both systemic and local applications. In 2000 he joined Tibotec, where he was responsible for early formulation of a number of new HIV compounds. In 2002 he joined Johnson & Johnson PRD (Janssen Pharmaceutica). As principal scientist he was responsible for the development of solid dosage forms. In this function he obtained two Johnson & Johnson awards, The Philip B. Hofmann Research Scientist Award and the Johnson Medal, the most prestigious award within Johnson & Johnson for his work on the formulation and spray drying technology for Intelence™, a novel NNRTI HIV drug. He has a broad experience in the formulation and process development of HIV, CNS, metabolic and oncology drugs. He has developed drug delivery systems from immediate release to controlled release, for water soluble to poorly soluble drugs, liquid to solid dosage forms. Jody was leading an innovation team within drug product development and was a member of the innovation taskforce of Janssen Pharmaceutica
Prof. Dr. Jean Paul Remon
Prof Dr. J.P. Remon is currently Dean of the Faculty of Pharmaceutical Sciences and Head of the Department of Pharmaceutics at Ghent University. Prof. Dr. J.P. Remon also serves as a Full Professor of Pharmaceutical Technology at Ghent University. Further, he is a member of the Registration Commission for Veterinary Drugs. Previously, Prof. Dr. J.P. Remon served as the Head of the Faculty Board at Ghent University. Additionally, he is an invited lecturer at the University of Brussels where he teaches a course on drug formulation aspects.
Throughout his career, Prof. Dr. J.P. Remon has given more than 235 posters and podium presentations surrounding drug delivery and formulation science at scientific meetings including, the American Association of Pharmaceutical Sciences Annual Meeting, International Symposium on Controlled Release, APGI/APV Conferences on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology. Prof. dr. J.P. Remon's work has appeared in nearly 240 peer reviewed publications including the Journal of Controlled Release, Annals of the New York Academy of Science, the Journal of Clinical Pharmacy, the Journal of Clinical Microbiology, Pharmaceutical Research and the American Journal of Cardiology. Further, he has secured more than 14 patents covering his research findings. Prof. Dr. J.P. Remon is a member of numerous scientific organisations including The Controlled Release Society, American Association of Pharmaceutical Scientists, Belgium Society of Pharmaceutical Sciences and the International Society of Pharmaceutical Engineering. Prof. Dr. J.P. Remon received a degree in Pharmaceutical Sciences (1973) and a second degree in Industrial Pharmacy (1974) from Ghent University. He also completed his Doctoral Degree in Pharmaceutical Sciences at Ghent University (1981). He was a postdoctoral fellow at the University of Keele (UK) (1983) and at the Philadelphia College of Pharmacy and Sciences (US) (1984).
Prof. Dr. Marc Van Ranst
Prof Dr. Marc Van Ranst is currently Head of the Department of Laboratory Medicine and Head of the Laboratory of Diagnostic Virology at the University of Leuven, Belgium. He teaches virology, epidemiology, and bioinformatics at the Faculty of Medicine at the University of Leuven and at the Hogeschool Leuven. Since 1995, he holds an affiliate academic position at the Faculty of Natural Sciences at Charles University in Prague, Czech Republic, where he teaches a Bioinformatics course. In 1998, he became board-licensed as a specialist in clinical biology. Since 1999, he is a professor at the University of Leuven, Belgium. In 2004 Professor Van Ranst was granted the European Clinical Virology Heine-Medin award of the European Society for Clinical Virology. In 2005, he received a doctor honoris causa degree at the University of Kalmar in Sweden. He is also the director of the AIDS reference laboratory and several national reference laboratories. Professor Van Ranst was inducted in 1999 to the Belgian high council for public health. In 2007, he was appointed by the Belgian Government as Interministerial Commissary for influenza pandemic preparedness planning.
In his research laboratory, nine PhD students and four master degree students are currently working on studies on the molecular evolution and epidemiology of DNA and RNA viruses. He published over 200 scientific papers in peer reviewed and Medline-indexed journals (such as Lancet, New England Journal of Medicine, Journal of Virology) and contributed chapters to six books on viral molecular evolution and bioinformatics.
Prof. Dr. Marc Van Ranst graduated as a medical doctor from the University of Leuven (1990). From 1985 on, he trained at the Rega Institute for Medical Research in Leuven. From 1990 to 1993, he worked at the department of microbiology & immunology at Albert Einstein College of Medicine in New York, and received his Ph.D. degree in virology in 1994.
Dr. Herman Van Cauteren
Dr. Van Cauteren has a doctoral degree of veterinary medicine and has worked in the pharmaceutical industry since 1978, specializing in toxicology.
He spent the first 20 years of his career in Belgium with Janssen Pharmaceutica and held positions of increasing responsibility in the Tox/Path/LAM department, up to Vice President of Preclinical Safety. From 1998 through 2003, Dr. Van Cauteren was the Global Head of Preclinical Development at Novartis in Switzerland. In this position, he was responsible for the preclinical safety assessment of human pharmaceuticals including bio-analysis, drug metabolism and pharmacokinetics for Europe, the USA, and Japan. In 2003, he returned to Belgium and joined Tibotec-Virco (a Johnson & Johnson Company specializing in antivirals) as Vice President, Drug Evaluation (Proof-of-Concept Testing) and Preclinical Development.
Since January 2005, Dr. Van Cauteren has served as the Head of Global PreClinical Development within Johnson & Johnson Pharmaceuticals R&D. In this position, he is in charge of the preclinical profiling of human pharmaceuticals, which spans the entire R&D continuum from research support for candidate screening and selection, through proof-of-concept testing, full development and registration, and Phase IV life cycle management. Dr. Van Cauteren's global responsibilities cover Toxicology, Pathology, Laboratory Animal Medicine, Bioanalysis, Preclinical Pharmacokinetics and Drug Metabolism.
The long-term goal for GPCD is to conduct preclinical study activities for all J&J R&D companies. In this respect, the J&J R&D companies are responsible for driving the projects forward, while tapping into GPCD for its core areas of expertise and centers of excellence.
In 2008 Dr. Van Cauteren founded Pharmaparacelsus as an independent expert in Preclinical Safety Assessment, Proof-of-Concept Testing and Preclinical Development of Pharmaceuticals.
Prof. Dr. Piet Stinissen
Prof. Dr. Piet Stinissen is Director of the Biomedical Research Institute (BIOMED) of Hasselt University and Professor of Biochemistry and Immunology at the Faculty of Medicine of Hasselt University. He heads a team of over 75 researchers and technical staff. Prof. Dr. Piet Stinissen's work has appeared in over 70 peer reviewed publications including Science, Lancet, Annals of Neurology, Journal of Immunology and Journal of Neuroimmunology,. Furthermore, he is co-inventor of two patent applications on biomarkers for autoimmune disease. Prof. Dr. Piet Stinissen is a member of numerous scientific organizations including the International Society of Neuroimmunology, the European School for Neuroimmunology (ESNI), the Belgian WOMS (MS research) foundation and the Belgian Immunological Society. Prof. Dr. Piet Stinissen received a degree in Biochemistry (1986) from Antwerp University. He completed his Doctoral Degree in Medical Sciences at Antwerp University (1992). He was a postdoctoral fellow at the Dr. Willemsinstituut, Head of the Autoimmune Disease Unit at BIOMED and Associate Professor of Biochemistry and Immunology at Hasselt University until he was appointed full professor in 2006. |
|
|
|
